The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great promise for the treatment of cancer. However, despite the success of these agents in treating chronic myelogenous leukemia (CML), the majority of patients continue to present with minimal residual disease contained within the bone marrow microenvironment. These clinical observations suggest that the bone marrow microenvironment may provide survival signals that contribute to the failure to eliminate minimal residual disease. The bone marrow microenvironment is comprised of multiple sub-domains which vary in cellular composition and gradients of soluble factors and matrix composition. Experimental evidence indicate that exposure of tumor cells to either bone marrow derived soluble factors or the extracellular matrix can confer a multi-drug resistance phenotype. Together, these data indicate that targeting such pathways may be a viable approach for increasing the efficacy of chemotherapy. Moreover, we propose that personalized medicine must go beyond understanding predictive models inherent to tumors but rather build predictive models that consider diversity in response due to interactions with the tumor microenvironment. Although review will focus on CML, understanding the contribution of the bone marrow microenvironment could contribute to rationale combination therapy in other types of leukemia, multiple myeloma and solid tumors which metastasize to the bone.
Nair
Rajesh R
RR
Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33612, United States.
Tolentino
Joel
J
Hazlehurst
Lori A
LA
D001853:Bone Marrow / Q000473:pathology*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D018365:Neoplasm, Residual; D014411:Neoplastic Stem Cells / Q000473:pathology
Blood. 2007 Jan 15;109(2):500-2
16990603
Trends Genet. 2003 Aug;19(8):458-66
12902164
Nature. 2003 Oct 23;425(6960):841-6
14574413
Nature. 2010 Jan 28;463(7280):501-6
20072125
Clin Cancer Res. 2006 Dec 15;12(24):7374-9
17189410
Leuk Lymphoma. 2000 Jun;38(1-2):71-81
10811449
Cancer Res. 2003 May 1;63(9):2118-26
12727828
Leukemia. 2007 May;21(5):926-35
17330101
Leukemia. 2009 Jun;23(6):1054-61
19282833
Blood. 1975 Jul;46(1):65-72
1131427
Lancet Oncol. 2007 Nov;8(11):1018-29
17976612
Leukemia. 2005 Jul;19(7):1198-206
15902298
Science. 2005 Aug 12;309(5737):1074-8
16099986
Cell Tissue Kinet. 1970 Apr;3(2):119-30
4399641
Leukemia. 2001 Aug;15(8):1232-9
11480565
Leuk Lymphoma. 2009 Oct;50(10):1676-86
19657955
Br J Haematol. 2007 Jan;136(2):269-75
17233818
J Natl Compr Canc Netw. 2009 Oct;7(9):1028-37
19878642
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63
17548814
Cancer Cell. 2008 Sep 9;14(3):238-49
18772113
Nat Med. 2006 Oct;12(10):1175-80
16998483
Blood. 2006 Jun 1;107(11):4532-9
16469872
Science. 2004 Jul 16;305(5682):399-401
15256671
Int J Hematol. 2009 Oct;90(3):281-291
19669860
Leukemia. 2004 Mar;18(3):401-8
14724652
Cytotherapy. 2005;7(5):393-5
16236628
Cancer Cell. 2005 Feb;7(2):129-41
15710326
Blood. 2007 Oct 1;110(7):2475-83
17615290
Blood. 2003 May 1;101(9):3722-9
12506037
Nature. 1973 Jun 1;243(5405):290-3
4126434
Semin Hematol. 2003 Apr;40(2 Suppl 2):80-2
12783380
Nat Rev Immunol. 2003 Oct;3(10):813-21
14523387
Cancer Biother Radiopharm. 2002 Aug;17(4):405-26
12396705
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8
12629218
Mol Cell Biol. 2004 Jul;24(14):6172-83
15226421
Blood. 2003 Jul 1;102(1):276-83
12623848
Cell. 2005 Jul 1;121(7):1109-21
15989959
Blood. 1996 Mar 15;87(6):2450-8
8630410
J Cell Physiol. 1998 Jul;176(1):57-66
9618145
Exp Hematol. 2000 Aug;28(8):875-84
10989188
Blood. 2002 May 15;99(10):3838-43
11986244
Exp Hematol. 1974;2(2):83-92
4455512
Nature. 1998 Apr 9;392(6676):565-8
9560152
Cell. 1987 Feb 27;48(4):549-54
3028640
Oncogene. 2003 Oct 2;22(43):6785-93
14555991
Blood. 2006 Jul 15;108(2):645-52
16537804
Nat Med. 1997 Jul;3(7):730-7
9212098
Haematologica. 2010 Jul;95(7):1081-9
20179085
Nature. 2003 Oct 23;425(6960):836-41
14574412
Blood. 2005 Jul 1;106(1):86-94
15769895
J Biophotonics. 2009 Nov;2(11):619-31
19847800
Blood. 1993 Oct 1;82(7):2031-7
8104535
Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10
12783368
Blood. 1998 Apr 1;91(7):2406-14
9516140
Blood. 2003 Aug 15;102(4):1249-53
12714498
Leukemia. 2007 May;21(5):949-55
17361218
Connect Tissue Res. 2008;49(3):203-6
18661343
Biochem Biophys Res Commun. 2004 Oct 22;323(3):728-30
15381060
Nature. 2004 Nov 18;432(7015):396-401
15549107
Blood. 1996 Sep 15;88(6):2267-78
8822948
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
2673568
Nature. 2006 Feb 2;439(7076):599-603
16382241
Leuk Lymphoma. 2006 Feb;47(2):207-22
16321850
Immunol Rev. 2004 Feb;197:75-88
14962188
Blood. 2005 Nov 1;106(9):3020-7
16037394
Leukemia. 2005 Oct;19(10):1835-8
15990864
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12804-9
10536003
Blood. 2008 Dec 15;112(13):4839-42
18818391
Lancet. 2004 May 1;363(9419):1439-41
15121408
Genes Dev. 2000 Jun 1;14(11):1293-307
10837022
Exp Hematol. 2004 Dec;32(12):1129-36
15588937
Genes Dev. 2007 Sep 15;21(18):2283-7
17761812
Blood. 2003 Feb 1;101(3):856-62
12393456
Cancer. 2007 Nov 1;110(9):2000-6
17849425
Exp Hematol. 1996 Feb;24(2):386-91
8641370
Cancer. 2006 Mar 1;106(5):1188-96
16444746
Blood. 2003 Oct 15;102(8):2728-30
12855591
Science. 1999 Feb 5;283(5403):845-8
9933168
N Engl J Med. 2004 Aug 12;351(7):657-67
15306667
J Exp Med. 2005 Apr 18;201(8):1307-18
15837815
Leukemia. 2005 Jun;19(6):1034-41
15815728
Ann Hematol. 1994 Feb;68(2):85-7
7511936
Cancer. 2009 Feb 1;115(3):551-60
19117345
Blood. 2003 Apr 15;101(8):3236-9
12446442
Leukemia. 2005 Oct;19(10):1774-82
16136169
Nature. 1983 Nov 17-23;306(5940):277-80
6580527
Nature. 1996 Aug 29;382(6594):833-5
8752281
Blood Cells. 1978;4(1-2):7-25
747780
Leuk Lymphoma. 2005 Nov;46(11):1531-44
16236607
Blood. 2001 Apr 15;97(8):2293-9
11290590
Clin Cancer Res. 2005 Jul 1;11(13):4941-7
16000593
Leuk Lymphoma. 2008 Apr;49(4):604-9
18398718
Crit Rev Oncol Hematol. 1994 Jun;16(3):201-24
8074802
Nature. 2003 May 22;423(6938):409-14
12717450
Blood. 2001 Mar 1;97(5):1404-12
11222387
Blood. 2004 May 1;103(9):3258-64
14726388
Mol Cell Biol. 2003 Dec;23(24):9349-60
14645544
Science. 2008 Dec 19;322(5909):1861-5
19095944
Science. 2001 Nov 30;294(5548):1933-6
11729320
Prog Clin Biol Res. 1981;59B:249-56
7279943
Blood. 2006 Jul 15;108(2):697-704
16597591
J Hematother Stem Cell Res. 2000 Dec;9(6):841-8
11177595
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5431-6
17374716
J Clin Oncol. 2010 Jan 20;28(3):424-30
20008622
Br J Haematol. 2005 Aug;130(3):373-81
16042686
Science. 1999 Apr 2;284(5411):143-7
10102814
Hematology Am Soc Hematol Educ Program. 2008;:436-42
19074122
Leukemia. 2007 Jun;21(6):1267-75
17519960
Nat Med. 2006 Apr;12(4):446-51
16565722
Cell Stem Cell. 2007 Aug 16;1(2):204-17
18371351
Cancer Res. 2002 Jan 1;62(1):188-99
11782377
Blood. 2004 Apr 15;103(8):3167-74
15070699
Blood Rev. 2006 May;20(3):161-71
16364518
Nature. 2003 May 15;423(6937):302-5
12714971
J Pathol. 2005 Feb;205(3):311-7
15682430
Blood. 1999 Mar 1;93(5):1658-67
10029595
Gene Ther. 2003 Apr;10(8):621-9
12692590
Blood. 2005 Feb 15;105(4):1815-22
15494428
Best Pract Res Clin Haematol. 2009 Sep;22(3):431-43
19959092
Blood. 2007 May 1;109(9):4006-15
17218385
Clin Pharmacol Ther. 2008 Feb;83(2):258-64
17568400
Cell. 2004 Jul 23;118(2):149-61
15260986
Nature. 1983 Nov 17-23;306(5940):239-42
6316147
Blood. 2001 Nov 1;98(9):2615-25
11675329
Haematologica. 2003 Aug;88(8):853-63
12935973
J Exp Med. 2005 Jun 6;201(11):1781-91
15928197
Nature. 2008 Jun 19;453(7198):1072-8
18469801
Nat Med. 2001 Jun;7(6):687-92
11385505
Crit Rev Oncol Hematol. 2009 Mar;69(3):187-98
18675551
Nat Med. 1999 Jun;5(6):662-8
10371505
Leukemia. 2004 Aug;18(8):1321-31
15215876
Blood. 2008 Apr 15;111(8):4355-64
18268096
Nat Med. 1996 May;2(5):561-6
8616716
Transplantation. 2003 Feb 15;75(3):389-97
12589164
Exp Hematol. 2003 Oct;31(10):890-6
14550804
Blood. 2007 Mar 1;109(5):2147-55
17090651
Blood. 1998 Nov 15;92(10):3829-40
9808576
Blood. 2003 Nov 15;102(10):3837-44
12881305
Blood. 2006 Jul 1;108(1):28-37
16522812
Blood. 2003 May 15;101(10):3794-800
12560227
Nature. 2003 Oct 30;425(6961):962-7
14574365
Clin Cancer Res. 2008 Jun 15;14(12):3881-8
18559609
Cancer Sci. 2009 Jul;100(7):1166-72
19432904
Cancer Res. 2001 Mar 1;61(5):1799-804
11280726
J Clin Invest. 1994 Oct;94(4):1383-9
7929813
Clin Cancer Res. 2002 Sep;8(9):2976-84
12231544
Leukemia. 2006 Oct;20(10):1767-73
16855631
Mol Cancer Ther. 2008 Oct;7(10):3169-75
18852120
Blood. 2002 Jan 1;99(1):319-25
11756187
N Engl J Med. 2006 Jun 15;354(24):2531-41
16775234
Blood. 2003 Mar 1;101(5):1692-7
12411300
Ann N Y Acad Sci. 1995 Dec 29;770:70-8
8597383
Blood. 2004 Dec 1;104(12):3739-45
15315971
N Engl J Med. 2001 Apr 5;344(14):1031-7
11287972
Leukemia. 2002 Nov;16(11):2190-6
12399961
Cancer Res. 2009 Mar 15;69(6):2384-92
19276351
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
Cancer Res. 2007 Feb 1;67(3):1030-7
17283135
Am J Physiol. 1959 Dec;197:1255-7
13843748
Cell Death Differ. 2005 Nov;12 Suppl 2:1473-7
16247493
Leuk Lymphoma. 1993;11 Suppl 1:245-53
8251904
Annu Rev Immunol. 2007;25:619-47
17201681
Blood. 2008 Feb 1;111(3):1039-43
17932248
Blood. 2005 Mar 1;105(5):2214-9
15514012
Blood. 2005 Mar 1;105(5):2093-8
15345592
N Engl J Med. 2006 Jun 15;354(24):2542-51
16775235
Mol Biol Cell. 2003 May;14(5):2071-87
12802076
Blood. 2002 Nov 15;100(10):3767-75
12393646
Blood. 2006 Sep 15;108(6):1809-20
16709930
Blood. 1995 Jun 15;85(12):3636-45
7780147
Immunity. 2006 Dec;25(6):977-88
17174120
Immunity. 2005 Feb;22(2):259-70
15723813
Cancer Res. 2006 Jul 1;66(13):6763-71
16818652
Blood. 2007 Jan 1;109(1):58-60
16973963